Cellcept Patient, Information, Instructions - Mycophenolate Mofetil

Cellcept Patient, Information, Instructions - Mycophenolate Mofetil

PATIENT INFORMATION

Patients should be informed of the need for repeated appropriate laboratory tests while they are receiving CellCept. Patients should be given complete dosage instructions and informed of the increased risk of lymphoproliferative disease and certain other malignancies. Women of childbearing potential should be instructed of the potential risks during pregnancy, and that they should use effective contraception before beginning CellCept therapy, during therapy and for 6 weeks after CellCept has been stopped (see WARNINGS and PRECAUTIONS: Pregnancy).